Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis by Moreira-Teixeira, L et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18703  | https://doi.org/10.1038/s41598-020-75734-x
www.nature.com/scientificreports
Airway delivery of both a BCG 
prime and adenoviral boost drives 
CD4 and CD8 T cells into the lung 
tissue parenchyma
Daryan A. Kaveh1*, M. Carmen Garcia‑Pelayo1, Naomi C. Bull1,3, Pedro J. Sanchez‑Cordon2, 
John Spiropoulos2 & Philip J. Hogarth1
Heterologous BCG prime‑boost regimens represent a promising strategy for an urgently required 
improved tuberculosis vaccine. Identifying the mechanisms which underpin the enhanced protection 
induced by such strategies is one key aim which would significantly accelerate rational vaccine 
development. Experimentally, airway vaccination induces greater efficacy than parenteral delivery; in 
both conventional vaccination and heterologous boosting of parenteral BCG immunisation. However, 
the effect of delivering both the component prime and boost immunisations via the airway is not well 
known. Here we investigate delivery of both the BCG prime and adenovirus boost vaccination via 
the airway in a murine model, and demonstrate this approach may be able to improve the protective 
outcome over parenteral prime/airway boost. Intravascular staining of T cells in the lung revealed that 
the airway prime regimen induced more antigen‑specific multifunctional CD4 and CD8 T cells to the 
lung parenchyma prior to challenge and indicated the route of both prime and boost to be critical to 
the location of induced resident T cells in the lung. Further, in the absence of a defined phenotype of 
vaccine‑induced protection to tuberculosis; the magnitude and phenotype of vaccine‑specific T cells in 
the parenchyma of the lung may provide insights into potential correlates of immunity.
Tuberculosis (TB) currently claims an estimated 1.5 million lives each year and is the leading cause of mortality 
by an infectious disease, overtaking HIV in  20151. Mycobacterium bovis bacille Calmette-Guérin (BCG) remains 
the only available vaccine against TB and whilst it provides valuable protection against severe childhood forms 
of  TB2,3; meta-analyses of multiple clinical trials indicate widely variable efficacy ranging from 0 to 80%4. These 
data and the continued high burden of TB leads to inevitable questioning of its use, despite being the most widely 
used human vaccine globally. Consequently, there is a substantial ongoing research effort to identify improved 
TB vaccines. Nonetheless, due to these aforementioned benefits and recent evidence there may be non-specific 
protection against other  infections5; it is unlikely to be withdrawn in the near future, and an improved TB vaccine 
strategy will likely include  BCG6. However, after a century of use, we still understand little of the mechanisms 
which underpin BCG-induced protective immunity. Such knowledge could identify a robust correlate of immu-
nity against TB, still urgently required to help facilitate the rational design of an improved vaccine.
Promising strategies for improved vaccines utilising BCG include boosting immunity with heterologous 
vaccines, with viral vectors used in several leading  approaches7–11. Delivery of viral-vectored boosts to the 
airway mucosa, to align with the natural route of Mycobacterium tuberculosis (Mtb) infection, induces superior 
protective efficacy compared to parenteral delivery in many  reports9,11,12. Numerous studies demonstrate that 
airway delivery of BCG improves protective efficacy over standard parenteral  injection13–19, but surprisingly, 
administration of both prime and heterologous boost by the airway has been much less investigated. To date, 
this approach has only been reported in promising data from a single study using a BCG-Modified Vaccinia 
virus Ankara (MVA) prime-boost  vaccination12.
Intravascular staining (IVS) to discriminate vascular associated cells in live animals has brought a new dimen-
sion to cellular immune analyses, allowing concurrent identification of cell phenotype and function together 
with location within an organ. This technique has identified lymphocyte populations in numerous non-lymphoid 
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tissues including the lung, and facilitated the discovery of tissue-resident memory T  cells20; implicated in immu-
nity to infectious diseases at both barrier and non-barrier  tissues21,22.
IVS has shown CD4 T cells induced by Mtb infection within the lung parenchyma provide optimal protection 
compared to CD4 T cells in lung  vasculature23,24. Tissue-resident T cells in the lung induced by TB vaccines are 
not yet well  described25–27. We have shown that intradermal BCG vaccination induces antigen-specific CD4 T 
cells in the  lung28, but few reside in the lung  parenchyma29.
We hypothesised that delivering the BCG prime immunisation via an airway route, rather than parenter-
ally, could further enhance the protective capacity induced by an airway delivered viral vectored boost. Using a 
murine model, combining a BCG prime-adenovirus boost  vaccine30 with IVS, we sought to determine whether 
direct immunisation of the lung mucosa, enhanced tissue-resident immunity within the lung and thus protective 
immunity to TB challenge.
Here, we demonstrate that compared to parenteral priming, airway delivered BCG induced higher frequencies 
of antigen-specific multifunctional CD4 and CD8 T cells residing in the lung parenchyma. These observations 
provide insights into potential correlates of immunity.
Results
Airway BCG priming enhances lung parenchymal CD4 T cell responses to boost vaccina‑
tion. To assess the impact of varying the route of the BCG prime delivery in a BCG prime/boost regimen, 
(schedule shown in Fig. 1), mice were vaccinated with BCG, by the intradermal or airway (intranasal) route. Six 
weeks later, they received a single adenovirus boost via the airway. Four weeks after the boost,  CD45+ vascular 
cells were stained in vivo; and after isolation and stimulation, antigen-specific vascular and parenchymal spleen 
and lung cells measured using flow cytometry (gating strategy illustrated in Supplementary Fig.  S1 online). 
Antigen-specific cells (termed  cytokine+) were identified producing any combination of IFN-γ, IL-2, TNF-α and 
IL-17.
In the spleen (Fig. 2A), intradermal BCG alone induced a significant frequency of  cytokine+ antigen-specific 
CD4 T cells (0.6%, p < 0.001 vs. Control). Regardless of the priming route, in animals receiving prime/boost 
vaccinations these responses were ~ 50% lower (both 0.3%, p < 0.05) compared to BCG only.
In the whole lung (Fig. 2B), intradermal BCG prime administration of the prime/boost vaccination did not 
enhance  cytokine+ CD4 T cell responses over BCG alone (1.3% vs 1%, p < 0.05 vs. Control). In contrast, when 
the BCG prime immunisation was delivered by airway administration, whole lung  cytokine+ responses were 
increased twofold (2.5%; p < 0.01 vs. intradermal BCG/Ad).
IVS allowed clear discrimination of vascular/parenchymal lung T cells; vascular-associated cells staining posi-
tive for CD45, whilst tissue-resident parenchymal cells remaining  unstained20 (representative sample Fig. 2C).
Analysis of  cytokine+ CD4 T cells derived from these compartments of the lung revealed distinct response 
patterns to varying the route of BCG prime vaccinations (Fig. 2D). Lung vascular cell responses resembled the 
spleen; intradermal BCG alone induced greater  cytokine+ cell frequencies than prime/boost (1.3%, p < 0.01 vs. 
Control). In contrast, cells derived from the lung parenchyma displayed a different response pattern; intradermal 
BCG alone induced negligible  cytokine+ frequencies (0.04%), increasing tenfold when boosted (0.5%). Most 
strikingly, varying the BCG prime route to the airway increased the immunogenicity of the boost vaccine 35-fold 
with parenchymal  cytokine+ responses representing 1.4% of total CD4 T cells within the lung (p < 0.0001 vs. all 
groups). To confirm these cell frequencies represented real changes in cell populations within the lung, actual 
cell numbers were calculated, confirming the same response pattern (Fig. 2E).
Figure 1.  Vaccination regimen schedules. Groups of mice were immunised with a placebo Control or BCG, 
delivered by either the Intradermal or Airway route. Six weeks later, corresponding groups of mice received a 
single boost immunisation with adenovirus expressing TB10.4 by the airway route (Ad). Four weeks after the 
boost for equivalent groups of mice, either the spleen and lung cells were isolated for immunological assessment 
or mice were challenged with ~ 200 CFU of M. bovis by the intranasal route. Bacterial burden in the spleen and 
lungs of challenged mice was then assessed both 4 and 8 weeks later.
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Figure 2.  Airway BCG priming enhances lung parenchymal CD4 T cell responses to boost vaccination. Groups of mice 
were immunised as per Fig. 1 and 4 weeks after the final immunisation they received an i.v. anti-CD45 antibody injection 
prior to euthanasia. Spleen- and lung-derived cells were in vitro stimulated and interrogated for TB10.4 antigen-specific 
cytokine production (IFN-γ, IL-2, TNF-α, IL-17) by intracellular staining and flow cytometric analysis (see supplementary 
Fig. S1). Graphs show the percentage of  cytokine+ CD4 T cells (exhibiting any combination of IFN-γ, IL-2, TNF-α and IL-17 
production) of the total CD4 T cells derived from (A) the spleen and (B) the whole lung. (C) A representative flow cytometry 
plot illustrating the CD45 intravascular staining obtained by the i.v. injection allowing the differentiation of the whole lung-
derived cells into those which resided in the tissue parenchyma  (CD45-) and those in the lung vasculature  (CD45+). Graphs 
showing the (D) percentage or (E) absolute number of  cytokine+ CD4 T cells which were resident in the lung vasculature or 
parenchyma. Bars represent the mean ± SEM (n = 5–11). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 2-way ANOVA with 
Tukey’s post-hoc test. Data representative of one experiment.
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Comprehensive analysis stratified the individual subsets of  cytokine+ CD4 T cells producing the different 
simultaneous combinations of IFN-γ, IL-2 and TNF-α (see Supplementary Fig. S2 online). Although analysed, 
no significant IL-17+ cell population was detected (data not shown). These data, summarised in Fig. 3A, indicate 
significantly predominant multifunctional CD4 T cells of: IFN-γ+IL-2+TNF-α+, IFN-γ+TNF-α+ or IL-2+TNF-α+ 
functional phenotypes. Individual functional subsets did not associate with specific tissue compartments, or 
immunisation regimens.
Airway BCG priming enhances both systemic and lung parenchymal CD8 T cell responses 
to boost vaccination. Immunisation with intradermal BCG alone failed to induce significant systemic 
(spleen) antigen-specific  cytokine+ CD8 T cells, with responses remaining at background levels (0.09% total 
spleen CD8, Fig. 4A). In contrast, boosting intradermal BCG enhanced systemic CD8 T cell responses 30 fold 
(2.7% total spleen CD8). However, delivering the BCG prime immunisation by airway; this response was further 
increased to almost 100 fold (93 fold, 8.4% total spleen CD8, p < 0.01).
When viewed as a whole organ, antigen-specific CD8 T cells derived from the lung (Fig. 4B) mirrored that 
of the spleen. Responses to intradermal BCG alone were minimal (0.18% of lung CD8 T cells), but enhanced 
tenfold by boosting (2.1% of lung CD8 T cells) and with an order of magnitude increase (72 fold) when BCG 
prime was delivered via the airway (13% of lung CD8 T cells, p < 0.01).
Figure 3.  Airway BCG priming of boost vaccination has no marked effect on the proportions of cytokine 
producing subsets.  Cytokine+ T cells derived from the spleen, lung vasculature and lung parenchyma, as 
described in Figs. 2 and 4, were subdivided into subsets producing the different simultaneous combinations 
of IFN-γ, IL-2 and TNF-α. Pie chart segments represent the mean frequency of the seven individual subsets 
as a proportion of the total  cytokine+ population of (A) CD4 and (B) CD8 T cells in the different tissue 
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Figure 4.  Airway BCG priming enhances both systemic and lung parenchymal CD8 T cell responses to boost 
vaccination. Groups of mice were immunised as per Fig. 1 and  cytokine+ cells derived from the spleen and 
lung detected as described in Fig. 2. Graphs show the percentage of  cytokine+ CD8 T cells (exhibiting any 
combination of IFN-γ, IL-2, TNF-α and IL-17 production) of the total CD8 T cells derived from (A) the spleen 
and (B) the whole lung. (C) A representative flow cytometry plot illustrating the CD45 intravascular staining. 
Graphs showing the (D) percentage or (E) absolute number of  cytokine+ CD8 T cells which were resident in the 
lung vasculature or parenchyma. Bars represent the mean ± SEM (n = 5–11). *p < 0.05, **p < 0.01, ***p < 0.001 
****p < 0.0001, 2-way ANOVA with Tukey’s post-hoc test. Data representative of one experiment.
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Compartmentalising lung CD8 T cells by IVS staining revealed the background level response induced by 
BCG alone was lung vasculature derived (0.17% of total lung CD8 T cells; Fig. 4D). In contrast to the spleen, lung 
vascular  cytokine+ CD8 T cell responses were only significantly boosted (~ sixfold) when the BCG prime was 
delivered via the airway (1.7%, p < 0.05, Fig. 4D). Analyses of the lung parenchyma-derived cells revealed, that 
whilst BCG alone failed to induce significant responses (0.01% total lung CD8 T cells), the pattern of responses to 
both boosting BCG and varying the route of BCG in the prime/boost reflected the response pattern observed in 
the whole lung. Intradermal BCG prime of the boost induced a 20 fold increase in the parenchymal responses (2% 
total lung CD8 T cells), while varying the BCG prime route to airway, significantly increased this response 120 
fold (12% total lung CD8 T cells, p < 0.05). These frequency changes were confirmed by cell numbers (Fig. 4E).
CD8 T cell functional subset stratification (Fig. 3B and Supplementary Fig. S3 online) indicate CD8 T cell 
responses differed from CD4 T cells with significant populations of bifunctional IFN-γ+TNF-α+ cells predominat-
ing. Functional subsets were not specific to the tissue location, and while only the BCG prime/boost vaccination 
regimens induced multifunctional CD8 T cells, the route of BCG priming did not affect this stratification.
Airway BCG priming confers a more sustained protective capacity to the boost vaccina‑
tion. In order to assess the influence of administering the BCG prime via the airway on protective efficacy, 
one month after the last vaccination equivalent groups of mice were also challenged with ~ 200 CFU of M. bovis 
by the intranasal route. Bacterial burden in the spleen and lungs was then assessed both at 4 and 8 weeks later. 
The result for the lungs is illustrated in Fig. 5 and those for the spleen in Supplementary Fig. S4 online.
Figure 5.  Airway BCG priming confers a more sustained protective capacity to the boost vaccination. 
Groups of mice were immunised and then challenged with ~ 200 CFU M. bovis as per schedule in Fig. 1. Four 
and eight weeks later, the lungs of individual mice in equivalent groups were removed, homogenised and 
bacteria enumerated. Bars represent the mean  Log10 CFU ± SEM (n = 7–14). *p < 0.05, **p < 0.01, ***p < 0.001 
****p < 0.0001, 1-way ANOVA with Tukey’s post-hoc test. Data representative of one experiment.
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At 4 weeks post-challenge the M. bovis burden in control mice was 6.3  Log10 CFU in the lungs and 3.8  Log10 
CFU in the spleen. Intradermal BCG alone induced protection of 2.1  Log10 CFU in the lungs (p < 0.0001 vs. 
Control) and 1.5  Log10 CFU in the spleen (p < 0.05 vs. Control). Intradermal BCG prime administration of the 
prime/boost vaccination led to an increase in this protection by a further 1.6  Log10 in the lungs (p < 0.001 vs. 
intradermal BCG) and 0.8  Log10 CFU in spleen (not statistically significant vs. intradermal BCG). When the 
BCG prime immunisation was delivered by airway administration it conveyed equivalent increases in protection 
over intradermal BCG alone: 1.1  Log10 CFU in the lungs (p < 0.01 vs. Intradermal BCG) and 1.1  Log10 CFU in 
spleen (p < 0.05 vs. Intradermal BCG). Of note, the group which received a Control/Ad did exhibit a protective 
effect approaching that of Intradermal BCG alone: of 1.6  Log10 CFU in the lungs (p < 0.001 vs. Control) and 0.6 
 Log10 CFU in spleen (not statistically significant vs. Control).
At 8 weeks post-challenge, the bacterial burden in control mice remained at 6.3  Log10 CFU in the lungs, but 
had increased to 5.4  Log10 CFU in the spleen. The protection afforded by intradermal BCG alone had decreased 
to 0.9  Log10 CFU in the lungs (p < 0.05 vs. Control) and had remained at 1.5  Log10 CFU in the spleen (p < 0.001 vs. 
Control). The added protection afforded by both the prime/boost vaccinations had increased to 1.5  Log10 CFU in 
the spleen (p < 0.01 vs. Intradermal BCG). However, in the lungs, intradermal administration of the BCG prime 
no longer offered a protective advantage over intradermal BCG alone (0.2  Log10 CFU, p = 0.9 vs. intradermal 
BCG), whilst in contrast using airway administration there remained a discernible reduction in bacterial burden, 
(0.7  Log10 CFU, p = 0.0517 vs. intradermal BCG).
Airway BCG priming of the boost vaccination displays an increased inflammatory reaction to 
challenge. In addition to the assessment of bacterial burden, samples of lung tissue from the same animals 
were also taken for histopathological analysis to assess the tissue pathology induced by the challenge. Lung tis-
sue sections were assessed for granulomatous inflammation visualised with Haematoxylin and Eosin (H & E) 
staining. Quantitative analysis of the mean score of the percentage area exhibiting this inflammation revealed no 
differences between vaccine regimen groups at 4 weeks post-challenge (data not shown). Differences were appar-
ent at 8 weeks post-challenge (Fig. 6), although not statistically significant. The mean pathology score in the lung 
sections from mice in the Control (1.6) and Control/Ad (1.5) regimens were greater compared to those which 
received intradermal BCG alone (0.3). Mice which received intradermal BCG prime administration of the boost 
vaccination had similarly deceased pathology score (0.1), but interestingly, those which were primed by airway 
administration displayed a mean pathology score closer to that observed in the two control regimens (1.1). In 
nearly all animals, granulomatous inflammation was accompanied by the presence of mycobacteria observed as 
acid-fast bacilli (data not shown).
Figure 6.  Airway BCG priming of the boost vaccination displays an increased inflammatory reaction to 
challenge. Groups of mice were immunised and then challenged with M. bovis as per Fig. 1, 8 weeks later 
the right post-caval pulmonary lobes were taken for histopathological examination using H & E staining. 
Bars represent the mean score of the percentage area of sections from each group exhibiting granulomatous 
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Increased PD‑1 expression associates with  cytokine+ T cells from the lung parenchyma. Defined 
predictors of protection are not available for TB vaccines, but lung tissue-resident cells may play a role. These 
responses are not yet well understood, model studies of Mtb  infection31 propose a role for the inhibitory receptor, 
programmed cell death-1 (PD-1) in protective responses against TB within the lung. To investigate this in the 
context of enhanced protection and further characterise the antigen-specific parenchymal T cells associated with 
that protection, expression of PD-1 was examined on the  cytokine+ CD4 and CD8 T cells derived from the two 
lung compartments. This was carried out prior to challenge, concurrently with the analysis described for Figs. 2 
and 4. There was no detectable association of the level of PD-1 expression by  cytokine+ cells between the differ-
ent vaccine regimens and expression of PD-1 was not unique to any specific cytokine producing cell subset (data 
not shown). Figure 7A illustrates the differential expression of PD-1 by compartmentalised lung  cytokine+ CD4 
T cells derived from mice which received the airway BCG prime. Comparison of the PD-1 staining intensity on 
these cells subdivided by the two compartments (Fig. 7B,C) revealed that for both  cytokine+ CD4 and CD8 T 
cells the median fluorescence intensity (MFI) of PD-1 was on average 1.6 fold (p < 0.0001) and 1.7 fold (p < 0.001) 
greater, respectively, on those derived from the lung parenchyma compared to the vasculature, supporting its 
association with tissue-resident cells.
Discussion
The need for a new TB vaccine is urgent and leading strategies proceeding into clinical trials are BCG prime—
heterologous boost regimens. In experimental studies, mucosal delivery via the airway has demonstrated greater 
efficacy than parenteral delivery. This is the case when  BCG13–19 or viral  vectors32–34 are used alone and also when 
viral vectors are used to boost a parenteral BCG  immunisation9,11,12. Here, we investigated the effect of delivering 
both the BCG prime, and adenoviral boost vaccination via the airway in a murine model of M. bovis challenge. 
Delivery of prime via the airway (intranasal) induced greater migration of antigen-specific multifunctional CD4 
and CD8 T cells into the lung parenchyma than the parenteral (intradermal) route, and displayed an indication 
that it could convey an improved protective outcome.
Despite sustained research in this area, the protective immune response against TB is still not well understood. 
It is clear that the primary protective immune response requires antigen-specific CD4 T cells producing IFN-γ 
(reviewed  in35). This may support a CD8 T cell response, which is required for optimal  protection36, however, the 
exact role of CD8 T cells is not well established. Studies of vaccination-induced CD8 T cells report that superior 
protection using viral vectored boosting associates with CD8 T cell  responses1130,37. Therefore, higher frequen-
cies of both antigen-specific CD4 and CD8 T cells appear to associate with better protection. Multifunctional 
antigen-specific T cells are also potential correlates of vaccine mediated  protection38 and our previous work 
using M. bovis challenge models support  this28,39. However, such generalised measurements do not offer a robust 
correlate of  protection40 and require increased granularity.
We have previously shown parenteral (intradermal) BCG immunisation induces a persistent population of 
antigen-specific CD4 T cells in the lungs of  mice28 and others provide evidence that these cells associated with 
 protection41. This has also been shown for CD8 T cells resident in the lung induced by adenoviral vaccination, 
which appear to proliferate in situ42. The location of antigen-specific T cells at the site of the challenge infection 
Figure 7.  Increased PD-1 expression associates with  cytokine+ T cells from the lung parenchyma. Groups of 
mice were immunised as per Fig. 1 and  cytokine+ CD4 and CD8 T cells derived from the lung parenchyma 
and lung vasculature compartments detected as described in Figs. 2 and 4. Cells were simultaneously stained 
for surface expression of PD-1. Representative flow cytometry (A) contoured bivariate plot and (B) histogram 
both showing the differential expression of PD-1 by  cytokine+ CD4 T cells derived from the vascular  (CD45+, 
grey filled line) and parenchymal  (CD45-, unfilled line) compartments of the lungs of mice receiving the airway 
BCG/Ad regimen. (C) Graphs showing the median fluorescence intensity (MFI) of PD-1 staining of  cytokine+ 
CD4 and CD8 T cells derived from the two lung compartments of mice receiving this vaccine regimen. Circles 




Scientific Reports |        (2020) 10:18703  | https://doi.org/10.1038/s41598-020-75734-x
www.nature.com/scientificreports/
has been proposed as a key element in vaccine induced protection against TB, by accelerating initial responses 
to  infection43. Horvath et al. report that BCG-induced lung tissue-resident (likely predominantly vascular) CD4 
T cells exhibit delayed proliferation, which can be ameliorated by prior residence in the airways, improving pro-
tective  outcome44. This infers that primed antigen-specific T cells located as close as possible to the lung airway 
may be able to offer an increased protective capacity.
The development of IVS allowed discrimination of tissue-resident cells into those which associate with the 
vasculature and the  parenchyma20. Antigen-specific lung parenchymal CD4 T cells are more protective than lung 
vascular cells in both Mtb23,24 and respiratory virus infection  models45. This supports the hypothesis that vac-
cination which can induce antigen-specific T cells in the lung parenchyma may be more protective to respiratory 
infection. Protection by a parenteral subunit TB vaccination has associated with parenchymal multifunctional 
CD4 T cells induced post-challenge25,26. Few studies have localised T cells by IVS in the context of TB vaccination 
prior to challenge. The majority of antigen-specific T cells isolated from whole lung are typically resident in the 
lung vasculature rather than the  parenchyma46, as was confirmed for parenteral BCG vaccinates in the current 
study and a recent  publication29. This more systemically distributed response, as observed in the spleen, was 
driven to the lung parenchyma with our adenoviral boost and amplified by airway priming.
Polarisation of antigen-specific responses toward CD8 T cells is a hallmark of virally vectored vaccines. 
Those induced in the lung lumen by an airway, but not parenteral, adenoviral TB vaccine is associated with its 
superior protective  effect34,42. As the frequency of these cells correlates with those in the lung  parenchyma27, the 
compartments are likely closely associated. This is supported by the ability of airway delivered BCG to induce 
antigen-specific CD4 T cells in both the lung tissue parenchyma and the airway  lumen19.
In the current study, at 4 week post-challenge airway prime/boost did not increase protection over that pro-
vided by parenteral prime/boost, although both approaches were significantly better than BCG alone. Evalua-
tion at 8 weeks post-challenge expands the window in which enhanced protection can be observed, as the level 
of protection induced by parenteral BCG wanes from 4 to 8 weeks post-challenge, as previously reported in 
Mtb47,48 and M. bovis49 challenge models. We observed that a reduction in bacterial burden (better than BCG 
alone) was more evident in the airway primed group, than the parenteral primed group. Although this was 
not quite statistically significant (p = 0.0517), we believe these data are compelling when viewed alongside the 
immunological parameters measured. To further support this finding, further experimentation employing more 
prolonged challenge or survival experiments could provide valuable insight. The equivalent level of protection 
for both boost regimens in the spleen at 8 weeks post-challenge may indicate parenteral BCG priming protects 
against bacterial dissemination to a degree which cannot be improved upon by airway BCG priming, observed 
within the parameters of our model. In previous work, we have observed airway BCG alone is no better than 
parenteral BCG in the spleen at 4 weeks post-challenge19.
In our model we employ challenge infection with M. bovis. With its high degree of genetic homology to Mtb50, 
a broader host range and greater  virulence51,52 (and unpublished data), it could provide a useful surrogate for 
laboratory strains of Mtb in murine models. To clarify this, it would be highly informative to directly compare the 
vaccine-induced protection provided by low dose aerosol challenge of mice with these two mycobacterial species.
Lung histopathology indicated that at 8 weeks post-challenge there was an increased trend for granulomatous 
inflammation in groups primed via the airway compared to the parenteral route. Although airway delivery of 
BCG alone is able to directly cause a measurable degree of such lung  pathology53,54, that observed in this study 
appeared to be associated only in response to challenge as was not present at 4 weeks post-challenge, when BCG 
presence in the lung would be expected to be higher. This may indicate enhanced immune responses, or more 
probable, a localised inflammatory environment induced by BCG bacilli. Further experimentation may clarify if 
pathology is maintained below that of unprotected control animals. In agreement, others have observed post-Mtb 
challenge, animals receiving airway delivered BCG, displayed increased lung pathology compared to parenteral 
 BCG54, highlighting the importance of evaluating vaccine safety in addition to efficacy and immunogenicity.
ICS staining and analyses reveal distinct functional phenotypes for cells which associate with enhanced 
protection, although it must be stressed, not a direct correlate. Our data demonstrate, BCG vaccination by any 
route induces antigen-specific multifunctional CD4 T cell (IFN-γ+IL-2+TNF-α+, IFN-γ+TNF-α+ or IL-2+TNF-α+) 
effector/effector memory phenotypes as described  previously28,39. Antigen-specific CD8 T cells were only induced 
by regimens including adenovirus vaccination; and were less multifunctional (IFN-γ+TNF-α+, IFN-γ+ and TNF-
α+), similar to that observed in our previous  work30, although at a much higher frequency.
We observed no correlation between specific lung location and T cell functional phenotype in any vaccine 
regimen. In contrast, Mtb infection induces specific CD4 T cell populations in the lung parenchyma with fewer 
IFN-γ producing  cells23. In contrast to our use of in vitro antigen stimulation, this study utilised MHC Class II 
tetramers to identify antigen-specific cells which requires the use of direct ex vivo ICS staining and data cannot 
be directly compared.
We were unable to undertake more comprehensive cell surface phenotyping in combination with ICS and IVS, 
but did measure expression of the immune checkpoint molecule PD-1 on tissue-resident antigen-specific T cells. 
Expression of PD-1 was enhanced on lung parenchyma resident  cytokine+ CD4 and CD8 T cells, compared to 
vascular associated cells, in agreement with other  reports23,24,31. PD-1 expression on tissue-resident cells during 
Mtb infection may regulate proliferative  ability55, and by downregulating IFN-γ induced pathology, protect from 
lethal  disease24,31, although its role in vaccination-induced protection in not yet established. The observed lower 
magnitude in changes to PD-1 expression, as reported  elsewhere56, may represent differences between infection 
and vaccination. In an effort to discover both the mechanisms and predictors of vaccine mediated protection, 
further concurrent analyses of other markers associated with parenchymal T cells, such as  CXCR323,27, would 
also be informative.
The antigen-specific lung parenchymal T cells in our study are likely to represent both effector and/or effec-
tor memory T  cells29, but based solely upon location in the lung parenchyma, we are as yet unable to confirm 
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whether they represent canonical tissue-resident memory T cells  (TRM)21 and merits further investigation in TB 
vaccine models.
Live BCG bacilli are able to persist in vaccinated mice for at least 18 months in the secondary lymphoid organs 
with little lung involvement after parenteral BCG  immunisation28. It is therefore possible BCG administered by 
the airway may cause similar persistence in the lung  tissue53,54 and thus influence antigen-specific T cells in the 
lung parenchyma via localised inflammatory  environments54. Whether this impacts immune protection merits 
further investigation in vaccine studies using BCG. It is formally possible that such BCG bacilli within the lungs 
could lead to underestimation of protective efficacy by adding to the mycobacterial burden. To rule this out, 
such techniques as genetic sequence analysis of recovered bacilli or use of selective culture media would be 
worthwhile in future studies.
Adenoviral vaccination alone did provide significant protection at 4 weeks post-challenge, although not to 
the extent described by  others11,47,57. There are several potential reasons for this: differences in antigens (Ag85a 
vs. TB10.4); vaccine preparation; or the challenge (M. bovis vs. Mtb). This protection was not associated with 
substantial antigen-specific T cell responses, however the small frequency of CD4 T cells in the lung parenchyma 
and CD8 T cells in the spleen may play a role.
It should be noted, our study was not designed to identify superior vaccine candidates, but to evaluate the 
potential of an airway prime—airway boost vaccination regimen and investigate immune mechanisms in a ‘bet-
ter than BCG’ scenario. Our data demonstrate that this approach could offer an advantage over parenteral BCG 
prime due to the induction of increased frequencies of antigen-specific CD4/8 T cells located specifically in the 
lung parenchyma, as such cells have been identified to have an increased protective capacity against Mtb and 
could play a significant role. Therefore, identifying lung compartment location of highly focussed T cell responses 
(e.g. multifunctional CD4/8 T cells with downregulated inhibitory functions) is a promising approach. It identi-
fies a strategy whereby combining: the specific location of vaccination-induced T cells; surface and functional 
phenotype mapping; and ‘better than BCG alone’ vaccination regimens which increase the frequency of such 
cells in the lung parenchyma, may identify key responses to further improve rational vaccine design against TB.
Materials and methods
Ethics. All animal work was carried out in accordance with the UK Animal (Scientific Procedures) Act 1986; 
under appropriate licences. The study protocol was approved by the APHA Animal Use Ethics Committee (UK 
PCD number 70/6905).
Animals. Female BALB/c mice were obtained from SPF facilities at Charles River UK Ltd. and used at 
8 weeks of age. All animals were housed in appropriate Advisory Committee on Dangerous Pathogens (ACDP) 
Containment Level 3 (equivalent to BSL3) facilities at APHA, according to the Code of Practice for the Housing 
and Care of Animals Bred, Supplied or Used for Scientific  Purposes58. All animals were randomly assigned to 
treatment groups in appropriate numbers and housed and cared for, including during the challenge period, as 
previously  described30.
Mycobacteria, mycobacterial enumeration, viral vectors and antigens. The vaccination strain 
was the human vaccine M. bovis BCG Danish 1331, reconstituted as per manufacturer’s instructions (SSI, 
Copenhagen, Denmark) in Sauton diluent (SSI) supplied with the original vaccine. Expression of TB10.4 protein 
in a type 5 Ad was undertaken as previously  described30 and prepared for immunisation in PBS.
M. bovis strain AF2122/97 was used for all challenge experiments as described  previously39.
Two immunodominant peptides (Pepscan, Lelystad, The Netherlands), [SSTHEANTMAMMARDT] and 
[AGY AGT LQSLGAEIAV] of the TB10.4 protein were used for in vitro antigen stimulations as these were previ-
ously found to contain the only CD4 and CD8 epitopes induced in this model,  respectively30.
Mycobacteria were enumerated in aseptically removed spleen and lungs from animals after euthanasia. Organs 
were homogenised, serially diluted and plated out onto modified Middlebrook 7H11 agar medium as previously 
 described59, except that homogenisation was carried out in 1 ml volumes utilising a Precellys 24 and CK28-R 
tubes (Bertin Instruments, Montigny-le-Bretonneux, France). Bacterial colonies were enumerated 4 weeks later 
following incubation at 37 °C.
Immunisation and challenge. There were five separate treatment groups of mice: Control (placebo); 
Intradermal BCG; Intradermal BCG/Ad; Airway BCG/Ad; and Control/Ad. Groups of mice were immunised 
with a single injection (50 µl) containing 2 × 105 CFU of Intradermal BCG in the base of the tail, or the same 
dose of BCG (or diluent only placebo) in 25 µl intranasally (i.n.). We refer to this i.n. delivery as airway, as our 
previous data demonstrated that 75% of inoculum delivered to the nares entered the  lungs49. Six weeks later cor-
responding groups of Control (placebo) or BCG immunised mice were boosted once, with 5 × 107 PFU (25 µl) 
of Ad-TB10.4 delivered i.n.. Four weeks later, six mice per group were euthanised for immunological analyses, 
and all remaining mice were challenged with ~ 200 CFU M. bovis i.n. as previously  described49. At both 4 and 
8 weeks post-challenge, the bacterial loads in the spleen and lungs of equivalent groups of mice were enumerated 
as previously described above. The right lung post-caval lobe was first separated for histopathological analysis. 
All i.n. inoculations were conducted under brief general anaesthesia with Isofluorane.
Cell isolation and stimulation. Immediately prior to euthanisation by cervical dislocation, 0.075 µg of 
anti-CD45 – PE (clone: 30-F11, BioLegend, London, UK) was delivered intravenously (i.v.) in 100 µl for exclu-
sive in vivo staining of intravascular cells. Following euthanasia, spleens and lungs were aseptically removed 
and cells prepared as previously  described39, except in order to prevent ex vivo staining, the lungs were immedi-
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ately homogenised with a GentleMACS dissociator (Miltenyi Biotec, Bisley, UK) and the homogenate diluted to 
20 ml. Following washing (300 g/8min), all cells were re-suspended at 1 × 107/ml for assays. Cells were cultured 
with a pool of both TB10.4 peptide antigens (see above) each at a final concentration of 2 µg/ml for all assays in 
addition to 1ug/ml anti-CD28 (clone: 37.51, BD Biosciences, Oxford, UK).
Flow cytometry. For intracellular staining (ICS), cells were cultured with the above antigen stimulation 
as previously  described39. Subsequently, they were surface stained with pre-titrated antibodies: CD4-APC-
H7 (clone: GK1.5, BD Biosciences); CD90.2—efluor450 (clone: 53-2.1) ; CD19—Biotin (clone: eBio1D3); 
CD16/32—Biotin (clone: 93, Life Technologies, Paisley, UK); PD-1—FITC (clone: 29F.1A12) ; CD8—Alexa 
Fluor 700 (clone: 53-6.7), CD44—Brilliant Violet (BV) 785 (clone: IM7) and Zombie Aqua Fixable Viability Dye 
(‘Zaqua’); followed by Streptavidin—BD Horizon BV711 (BD Biosciences). Subsequently, cells were washed, 
fixed/permeabilised and stained by ICS with IFN-γ—PE-Cy7 (clone: XMG1.2); IL-2—APC (clone: JES6-5H4); 
IL-17a—BV605 (clone: TC11-18H10.1); and TNF-α—PerCP-Cy5.5 (clone: MP6-XT22, BD Biosciences) as pre-
viously  described39. All antibody conjugates/dyes were purchased from Biolegend except where stated.
Cells were analysed immediately after final staining. Data were acquired using a SORP LSR Fortessa (BD 
Bioscience) (utilizing a 532 nm laser for PE and PE-Cy7) and analyzed on Flowjo v.10.1 (BD Bioscience) soft-
ware. All analyses were gated on a minimum of 100,000 live lymphocytes. Compensation was performed using 
UltraComp eBeads (Life Technologies) according to the manufacturer’s instructions. Fluorescence minus one 
(FMO) controls were used to set gates for cytokine analyses.
Histopathological analysis. Lung tissue samples were fixed in 4% buffered formalin solution, routinely 
processed and embedded in paraffin wax for histopathological studies. Paraffin-embedded tissue blocks were 
sectioned at 4 μm thickness and stained with haematoxylin and eosin (H & E). A blind histopathologic evalua-
tion was carried out on H & E stained sections by a qualified pathologist. Manual scoring based on the approxi-
mate percentage of lung area affected by granulomatous inflammation was carried out as follows: 0% (0); < 5% 
(1); 5–20% (2); 21–40% (3); 41–60% (4); 61–80% (5); > 80% (6). Serial sections were also stained by the conven-
tional Ziehl–Neelsen staining method in order to confirm the presence of acid-fast bacilli (AFB) in the pulmo-
nary granulomatous lesions.
Statistical analysis. Bacterial burden data were analysed by 1-way ANOVA and ICS by 2-way ANOVA, 
all with Tukey’s post-hoc test. Prior to analysis, mycobacterial counts were  log10 transformed (Y = log[Y]) and 
expressed as  log10/organ. PD-1 expression was analysed using a two-tailed paired t-test. Histopathological data 
were analysed by Kruskal–Wallis test. Statistical analyses were carried out using GraphPad Prism 7 software 
(GraphPad, USA). Differences with a p < 0.05 were considered significant and denoted with *, p < 0.01 with **, 
p < 0.001 with *** and p < 0.0001 with ****.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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